Categories: Herbal Therapeutics

Why NEUROOTS Strongly Advises Against Canna Use Before Age 18

A message from our community to parents, young members, and future farmers
We believe in growing with awareness, responsibility, and care for both the plant and the people.

While we respect cannabis as a natural herb with a long agricultural and cultural history, we are also committed to science and the well-being of our younger community members. For this reason, we do not recommend and actively discourage cannabis use by anyone under 18 years old.

Here’s what decades of scientific research tell us about the developing brain and cannabis: The brain continues developing until about age 25

The prefrontal cortex – responsible for decision-making, impulse control, planning, and emotional regulation – is one of the last areas to mature.

THC (the main psychoactive compound in cannabis) interferes with this critical development process.

People who start using cannabis before age 18 are 4–7 times more likely to develop cannabis use disorder later in life (Winters & Lee, 2008; Substance Abuse and Mental Health Services Administration data).

Today’s cannabis is significantly stronger

Average THC concentration in Europe and North America has risen from ~4% in the 1990s to 15–25% or higher today (and even 90%+ in concentrates). This dramatic increase in potency amplifies all the risks listed above.

We welcome open, honest conversations about cannabis, its history, and its responsible adult use. But protecting the developing minds of our younger members and children of our community is non-negotiable.

Until the brain is fully mature – ideally age 21 or older – the potential risks far outweigh any perceived benefits.

neuroots.co

Recent Posts

Assessment of Cannabidiolic Acid’s Neuroprotective Potential in a TDP-43 Transgenic Mouse Model of Amyotrophic Lateral Sclerosis

Cannabinoids originating from plants, such as Δ9-tetrahydrocannabinol (Δ9-THC), cannabinol, and formulations resembling Sativex, have demonstrated…

4 months ago

Peptides, NAD⁺, and MOTS-c: Evidence-Based Insights into Their Roles in Longevity as of 2025

In the domain of longevity research, peptides have garnered significant attention, yet only a subset…

4 months ago

A Unified Prime Editing Strategy for Mitigating Diverse Genetic Disorders

Advancements in genome editing have introduced a novel approach capable of addressing a substantial proportion…

4 months ago

Revolutionizing ALS Clinical Trials: A New Era Ahead

ALS research is transforming rapidly! From isolated studies to global networks, trials now boost patient…

4 months ago

Targeting Aging Pathways with GLP-1 Analogs: From Metabolic Disorders to Healthspan Extension

During the August convening of the Aging Research and Drug Discovery conference in Copenhagen, representatives…

4 months ago

Assessment of Residual Plasmid DNA and SV40 Promoter-Enhancer Elements in modRNA-Based COVID-19 Vaccines from Pfizer-BioNTech and Moderna Sourced in Ontario, Canada

David J. Speicher and colleagues. Autoimmunity. 2025 Dec;58(1):2551517. doi: 10.1080/08916934.2025.2551517. Epub 2025 Sep 6. Abstract…

4 months ago